Breast cancer drug approvals issued by EMA: A review of clinical trials

Simona Duranti; Alessandra Fabi; Marco Filetti; Rosa Falcone; Pasquale Lombardi; Gennaro Daniele; Gianluca Franceschini; Luisa Carbognin; Antonella Palazzo; Giorgia Garganese; Ida Paris; Giovanni Scambia; Antonella Pietragalla

doi:10.3390/cancers13205198

Breast cancer drug approvals issued by EMA: A review of clinical trials

Simona Duranti, Alessandra Fabi, Marco Filetti, Rosa Falcone, Pasquale Lombardi, Gennaro Daniele, Gianluca Franceschini, Luisa Carbognin, Antonella Palazzo, Giorgia Garganese, Ida Paris, Giovanni Scambia, Antonella Pietragalla

Risultato della ricerca: Contributo in rivista › Articolo in rivista

Abstract

Breast cancer represents the first cause of cancer worldwide and the leading cause of cancer mortality for women. Therefore, new therapies are needed to improve the prognosis of women diagnosed with this disease. In this review, we summarize the new drug indications for the treatment of breast cancer approved by European Medicines Agency between January 2015 and June 2021. In particular, we analyzed the clinical trials results leading to approvals and their update (when available), according to setting (localized and locally advanced or metastatic) and clinical features (hormone receptor positive, HER2 positive, triple negative, BRCA 1/2 mutation). The aim of this paper is to describe the clinical benefit obtained with the new indications.

Lingua originale	English
pagine (da-a)	1-17
Numero di pagine	17
Rivista	Cancers
Volume	13
DOI	https://doi.org/10.3390/cancers13205198
Stato di pubblicazione	Pubblicato - 2021

Keywords

Breast cancer
Drugs approval
EMA

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.3390/cancers13205198

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

@article{5e6d87e871d0403798e41dce05aea588,

title = "Breast cancer drug approvals issued by EMA: A review of clinical trials",

abstract = "Breast cancer represents the first cause of cancer worldwide and the leading cause of cancer mortality for women. Therefore, new therapies are needed to improve the prognosis of women diagnosed with this disease. In this review, we summarize the new drug indications for the treatment of breast cancer approved by European Medicines Agency between January 2015 and June 2021. In particular, we analyzed the clinical trials results leading to approvals and their update (when available), according to setting (localized and locally advanced or metastatic) and clinical features (hormone receptor positive, HER2 positive, triple negative, BRCA 1/2 mutation). The aim of this paper is to describe the clinical benefit obtained with the new indications.",

keywords = "Breast cancer, Drugs approval, EMA, Breast cancer, Drugs approval, EMA",

author = "Simona Duranti and Alessandra Fabi and Marco Filetti and Rosa Falcone and Pasquale Lombardi and Gennaro Daniele and Gianluca Franceschini and Luisa Carbognin and Antonella Palazzo and Giorgia Garganese and Ida Paris and Giovanni Scambia and Antonella Pietragalla",

year = "2021",

doi = "10.3390/cancers13205198",

language = "English",

volume = "13",

pages = "1--17",

journal = "Cancers",

issn = "2072-6694",

publisher = "Basel : MDPI",

}

TY - JOUR

T1 - Breast cancer drug approvals issued by EMA: A review of clinical trials

AU - Duranti, Simona

AU - Fabi, Alessandra

AU - Filetti, Marco

AU - Falcone, Rosa

AU - Lombardi, Pasquale

AU - Daniele, Gennaro

AU - Franceschini, Gianluca

AU - Carbognin, Luisa

AU - Palazzo, Antonella

AU - Garganese, Giorgia

AU - Paris, Ida

AU - Scambia, Giovanni

AU - Pietragalla, Antonella

PY - 2021

Y1 - 2021

N2 - Breast cancer represents the first cause of cancer worldwide and the leading cause of cancer mortality for women. Therefore, new therapies are needed to improve the prognosis of women diagnosed with this disease. In this review, we summarize the new drug indications for the treatment of breast cancer approved by European Medicines Agency between January 2015 and June 2021. In particular, we analyzed the clinical trials results leading to approvals and their update (when available), according to setting (localized and locally advanced or metastatic) and clinical features (hormone receptor positive, HER2 positive, triple negative, BRCA 1/2 mutation). The aim of this paper is to describe the clinical benefit obtained with the new indications.

AB - Breast cancer represents the first cause of cancer worldwide and the leading cause of cancer mortality for women. Therefore, new therapies are needed to improve the prognosis of women diagnosed with this disease. In this review, we summarize the new drug indications for the treatment of breast cancer approved by European Medicines Agency between January 2015 and June 2021. In particular, we analyzed the clinical trials results leading to approvals and their update (when available), according to setting (localized and locally advanced or metastatic) and clinical features (hormone receptor positive, HER2 positive, triple negative, BRCA 1/2 mutation). The aim of this paper is to describe the clinical benefit obtained with the new indications.

KW - Breast cancer

KW - Drugs approval

KW - EMA

KW - Breast cancer

KW - Drugs approval

KW - EMA

UR - http://hdl.handle.net/10807/190386

U2 - 10.3390/cancers13205198

DO - 10.3390/cancers13205198

M3 - Article

SN - 2072-6694

VL - 13

SP - 1

EP - 17

JO - Cancers

JF - Cancers

ER -

Breast cancer drug approvals issued by EMA: A review of clinical trials

Abstract

Keywords

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo